Short communication
The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning disabilities
Article first published online: 29 OCT 2009
DOI: 10.1111/j.1471-0528.2009.02372.x
© 2009 The Authors Journal compilation © RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology
Issue

BJOG: An International Journal of Obstetrics & Gynaecology
Special Issue: The gynaecological and reproductive health problems of puberty and adolescence
Volume 117, Issue 2, pages 216–221, January 2010
Additional Information
How to Cite
Pillai, M., O’Brien, K. and Hill, E. (2010), The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or physical or learning disabilities. BJOG: An International Journal of Obstetrics & Gynaecology, 117: 216–221. doi: 10.1111/j.1471-0528.2009.02372.x
Publication History
- Issue published online: 9 DEC 2009
- Article first published online: 29 OCT 2009
- Accepted 22 July 2009. Published online 29 October 2009.
- Abstract
- Article
- References
- Cited By
Keywords:
- Adolescent menstrual problems;
- levonorgestrel IUS
Please cite this paper as: Pillai M, O’Brien K, Hill E. The levonorgestrel IUS (Mirena) for the treatment of menstrual problems in adolescents with medical disorders or physical or learning disabilities. BJOG 2010;117:216–221.
Menstrual problems are common in adolescence. Management can be very problematic in girls with disability or medical disorders, as their condition and other medications may mean they are less likely to achieve satisfactory control with standard medical treatments. Those with disability tend to tolerate menses poorly. We report experience with the levonorgestrel intrauterine system (LNG IUS) for treatment of menstrual problems in adolescents with a range of medical problems or with severe learning disability. It provided of significant therapeutic benefit for 12 of 14 participants, with the majority opting to continue for the 5-year duration of the device. The rates of expulsion, bleeding and amenorrhoea appear similar to those reported in older women, where contraception is the primary indication.

1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)